Work

NRG BN002: Phase I study of checkpoint inhibitors anti-CTLA-4, anti-PD-1, the combination in patients with newly diagnosed glioblastoma.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.2053

Authors: Andrew E. Sloan, Mark R. Gilbert, Peixin Zhang, Kenneth D. Aldape, Jing Wu, Lisa R. Rogers, Patrick Y. Wen, Igor J. Barani, Fabio Massaiti Iwamoto, Raju R. Raval, Alfredo Daniel Voloschin, John Frederick De Groot, Minhee Won, Minesh P. Mehta

Institutions: University Hospitals Cleveland Medical Center, The University of Texas MD Anderson Cancer Center, NRG Oncology, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University Hospitals of Cleveland, Harvard University, Dana-Farber Brigham Cancer Center, University of California, San Francisco, Columbia University Irving Medical Center, The Ohio State University Wexner Medical Center, Emory University, University of Maryland Medical Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890580145

Cites:

Cited by: 6

Related to: 10